TRPC6 Inhibitor BI 764198 in Focal Segmental Glomerulosclerosis: Phase 2 Study Design

Abstract

Focal segmental glomerulosclerosis (FSGS), a leading glomerular cause of kidney failure, is a histological pattern characterized by podocyte injury and depletion.1 FSGS is found in 20–30% of adults with nephrotic syndrome and up to 20% of patients receiving dialysis.2,S1 FSGS can be broadly categorized into four causative classifications: primary (idiopathic), secondary (adaptive), familial (genetic), and of unknown cause.1,3,S2 Depending on patient selection and region, genetic variants have been reported in up to 14% of individuals with adult-onset FSGS.